PFE•benzinga•
Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer
Summary
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 14, 2025 by benzinga